Here’s what you should know:
1. Tenapanor’s first phase III trial failed to improve individual bowel movement rates, the study’s secondary endpoint.
2. Tenapanor conducted a second phase III trial. Researchers found the combined responder rate for six of 12 weeks demonstrated that 36.5 percent of Tenapanor patients had at least a 30 percent reduction in abdominal pain and increased spontaneous bowel movements for at least six of the 12-week treatment period.
3. Tenapanor patients experienced an increase in diarrhea when compared with a placebo. Diarrhea is an adverse event of most IBS-C therapies.
4. Tenapanor reached statistical significance for the study and in abdominal pain responder rates. Tenapanor had a consistent response across 26 weeks of the study.
More articles on gastroenterology:
GI center to know: South Brooklyn Endoscopy Center
Illinois Gastroenterology Group, Rome Memorial Hospital & more: 3 GI practices in the news
Immuron receives patent for NASH treatment — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
